N,N-二(三甲基硅基)乙酰胺 | 10416-58-7

• 物质功能分类: 有机原料 - 氨基化合物 - 酰胺类化合物
• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 中文名称: N,N-二(三甲基硅基)乙酰胺
• 英文名称: N,N-bis(trimethylsilyl)acetamide
• 英文别名: Bis(trimethylsilyl)acetamide；BSA
• CAS: 10416-58-7
• 化学式: C₈H₂₁NOSi₂
• 分子量: 203.432
• InChiKey: VTACLVUOTMPORB-UHFFFAOYSA-N

物化性质

• 沸点：
  67.5 °C(Press: 30 Torr)
• 密度：
  0.860±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2931900090

SDS

Name:	n n-bis(Trimethylsilyl)acetamide Material Safety Data Sheet
Synonym:
CAS:	10416-58-7

Section 1 - Chemical Product MSDS Name:n n-bis(Trimethylsilyl)acetamide Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
10416-58-7	Acetamide, n,n-bis(trimethylsilyl)-		233-891-1

Hazard Symbols: F
Risk Phrases: 11

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Appearance: clear very faint yellow. Flash Point: 12 deg C.
Not available.
Target Organs: None.
Potential Health Effects
The toxicological properties of this material have not been investigated. Use appropriate procedures to prevent opportunities for direct contact with the skin or eyes and to prevent inhalation.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
Remove contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Keep container closed when not in use.
Flammables-area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits +--------------------+-------------------+-------------------+-----------------+ | Chemical Name | ACGIH | NIOSH |OSHA - Final PELs| |--------------------|-------------------|-------------------|-----------------| | Acetamide, n,n-bis(|none listed |6 mg/m3 TWA |none listed | | trimethylsilyl)- | | (listed under ** | | | | |no name **).3000 | | | | | mg/m3 IDLH | | | | | (listed under ** | | | | |no name **). | | +--------------------+-------------------+-------------------+-----------------+ OSHA Vacated PELs: Acetamide, n,n-bis(trimethylsilyl)-: No OSHA Vacated PELs are listed for this chemical.
Personal Protective Equipment Eyes: Wear chemical goggles.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant a respirator's use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Not available.
Appearance: clear very faint yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 53 deg C @ 15.00mm Hg
Freezing/Melting Point: 0 deg C
Autoignition Temperature: Not available.
Flash Point: 12 deg C ( 53.60 deg F)
NFPA Rating: Not published.
Explosion Limits, Lower: Not available.
Upper: Not available.
Decomposition Temperature:
Solubility:
Specific Gravity/Density: 1.4180g/cm3
Molecular Formula: C8H21NOSi2
Molecular Weight: 203.43

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Not available.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 10416-58-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Acetamide, n,n-bis(trimethylsilyl)- - IARC: Group 3 carcinogen (listed as ** undefined **).
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Chemical waste generators must determine whether a discarded chemical is classif as a hazardous waste.
US EPA guidelines for the classification determination are listed in 40 CFR Part Additionally, waste generators must consult state and local hazardous waste regu ensure complete and accurate classification.
RCRA P-Series: None listed.
RCRA U-Series: None listed.

---

Section 14 - TRANSPORT INFORMATION

CDG/CPL
Not classified as hazardous for supply.
Canadian TDG
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: F
Risk Phrases:
R 11 Highly flammable.
Safety Phrases:
S 16 Keep away from sources of ignition - No
smoking.
WGK (Water Danger/Protection)
CAS# 10416-58-7: No information available.
United Kingdom Occupational Exposure Limits
CAS# 10416-58-7: OES-United Kingdom, TWA (listed as ** undefined
**): total inhalable dust: 6 mg/m3 TWA; respirable dust: 2.4 mg/m3
TWA
Canada
CAS# 10416-58-7 is listed on Canada's DSL/NDSL List.
WHMIS: Not available.
CAS# 10416-58-7 is not listed on Canada's Ingredient Disclosure List.
Exposure Limits
CAS# 10416-58-7: Not available.
US FEDERAL
TSCA
CAS# 10416-58-7 is listed on the TSCA inventory.
Health & Safety Reporting List
None of the chemicals are on the Health & Safety Reporting List.
Chemical Test Rules
None of the chemicals in this product are under a Chemical Test Rule.
Section 12b
None of the chemicals are listed under TSCA Section 12b.
TSCA Significant New Use Rule
None of the chemicals in this material have a SNUR under TSCA.
SARA
Section 302 (RQ)
None of the chemicals in this material have an RQ.
Section 302 (TPQ)
None of the chemicals in this product have a TPQ.
SARA Codes
CAS # 10416-58-7: flammable, reactive.
Section 313
No chemicals are reportable under Section 313.
Clean Air Act:
This material does not contain any hazardous air pollutants.
This material does not contain any Class 1 Ozone depletors.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N,N-二(三甲基硅基)乙酰胺 在 硫酸氢铵 、 氯磺酰异氰酸酯 作用下， 以 乙腈 为溶剂， 反应 48.0h， 生成 碘代三甲硅烷
  参考文献：
  名称：

  Some Aspects on Acyclonucleoside Synthesis

  摘要：

  An acyclonucleoside synthesis was investigated on the regioselective introduction of an acyclochain. We found that iodotrimethylsilane catalyzed the reaction of acyclochain introduction as well as its migration from S-2 to N-1 of 2-thiothymine and from N-7 to N-9 position of guanine. By taking the findings into account, several acyclonucleosides were synthesized in a simple one-pot procedure.

  DOI：

  10.1080/07328319808004313
• 作为产物：
  描述：

  sodium hexamethyldisilazane 以 甲苯 为溶剂， 反应 9.0h， 生成 N,N-二(三甲基硅基)乙酰胺
  参考文献：
  名称：

  有机合成中的酰基碘。与取代的双（三甲基甲硅烷基）胺的反应

  摘要：

  DOI：

  10.1134/s1070428013010259
• 作为试剂：
  描述：

  3-{2-[3-(fluorophenyl)-3-(trimethyl silyloxy)-propyl]-3-(4-fluoro phenyl amino)-3-(4-trimethyl silyloxy phenyl)-1-oxo-propyl}-4-(S)-phenyl oxazolidin-2-one 在 四丁基氟化铵 、 N,N-二(三甲基硅基)乙酰胺 、 硫酸 作用下， 以 甲苯 、 甲醇 、 水 为溶剂， 反应 2.0h， 生成 依泽替米贝
  参考文献：
  名称：

  Polymorphs of ezetimibe and process for preparation thereof

  摘要：

  本发明涉及埃泽替米布的新结晶形式和无定形形式及其制备方法。

  公开号：

  US20050171080A1

文献信息

• Matrix metalloprotease inhibitors
  申请人：Syntex (U.S.A.), Inc.

  公开号：US06013792A1

  公开（公告）日：2000-01-11

  Compounds of formula (I): ##STR1## as single stereoisomers or mixtures thereof and their pharmaceutically acceptable salts inhibit matrix metalloproteases, such as interstitial collagenases, and are useful in the treatment of mammals having disease states alleviated by the inhibition of such matrix metalloproteases, for example arthritic diseases or bone resorption disease, such as osteoporosis.

  公式（I）的化合物：##STR1##，作为单一立体异构体或其混合物及其药学上可接受的盐，抑制基质金属蛋白酶，如间质胶原酶，并且在治疗通过抑制这种基质金属蛋白酶而缓解的哺乳动物疾病状态中有用，例如关节炎性疾病或骨吸收疾病，如骨质疏松症。
• Pharmaceutically useful pyrazolopyridines
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04925849A1

  公开（公告）日：1990-05-15

  The disclosure deals with a pyrazolopyridine compound of the formula ##STR1## wherein the variables are defined in the specification. The compounds are useful as a diuretic, antihypertensive agent, etc.

  该披露涉及公式为##STR1##的吡唑吡啶化合物，其中变量在规范中定义。这些化合物可用作利尿剂、降压药剂等。
• 3-Substituted-7-substituted alkanamido-3-cephem-4-carboxylic acid
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04254260A1

  公开（公告）日：1981-03-03

  3-Substituted-7-substituted alkanamido-3-cephem-4-carboxylic acid compounds and pharmaceutically acceptable salts thereof which have antimicrobial activities, processes for the preparation thereof, pharmaceutical compositions comprising the same, and methods of using the same therapeutically in the treatment of infections.

  3-取代-7-取代烷基氨基-3-头孢烯-4-羧酸化合物及其具有抗微生物活性的药用盐，其制备方法，包括相同化合物的药物组合物，以及在治疗感染方面的治疗使用方法。
• Syn-isomer of 3,7-disubstituted-3-cephem-4-carboxylic acid compounds and
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04304770A1

  公开（公告）日：1981-12-08

  Preparation of pharmaceutical composition comprising, treatment of human and animal diseases with, and compound of, 3,7-disubstituted-3-cephem-4-carboxylic acid.

  含有3,7-二取代-3-头孢烯-4-羧酸的制药组合物的制备，以及用于治疗人类和动物疾病的化合物。
• Nucleotide mimics and their prodrugs
  申请人：——

  公开号：US20040059104A1

  公开（公告）日：2004-03-25

  The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

  本发明涉及核苷二磷酸模拟物和核苷三磷酸模拟物，其中包含二磷酸或三磷酸基团模拟物，以及可选的糖修饰和/或碱基修饰。本发明的核苷酸模拟物，以药学上可接受的盐、药学上可接受的前药或药物配方的形式，可用作抗病毒、抗微生物和抗癌剂。本发明提供了一种治疗病毒感染、微生物感染和增生性疾病的方法。本发明还涉及包含本发明化合物的药物组合物，可选地与其他药理活性剂结合。